ResMed Awarded Group Purchasing Contract with Premier

  • Premier members benefit from ResMed’s best-in-class non-invasive ventilators and interfaces
  • ResMed offerings include Astral™, Lumis™ Tx, Stellar™, AcuCare™ NIV masks and associated accessories
  • Three-year contract begins July 1, 2016

SAN DIEGO, June 28, 2016 – ResMed (NYSE:RMD), the world's leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care, today announced it has been awarded a three-year supplier group purchasing contract with Premier, a leading healthcare improvement company. Premier unites an alliance of approximately 3,600 U.S. hospitals and 120,000 other providers to transform healthcare.

This new contract will enable Premier-member hospitals and providers to offer their patients the latest in non-invasive ventilation (NIV) technology. From patients with diagnosed sleep apnea to COPD patients requiring NIV during an acute exacerbation, ResMed’s NIV products will provide Premier hospitals with the innovative tools they need to be effective in their treatment.

“The chance to offer the life-changing benefits of NIV therapy to more patients is very exciting and we’re privileged to play a part in that,” said Jon Yerbury, vice president of marketing, ResMed Americas. “Partnering with Premier also expands our market and provides us with more feedback from patients and providers to help drive our next innovations and keep pushing the boundaries in the medical technology space.”

About ResMed

ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.

ResMed.com | Facebook | Twitter | LinkedIn